Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
Status:
Completed
Trial end date:
2009-07-26
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth and by blocking blood flow to the tumor. Giving temozolomide together with sorafenib
may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying two different schedules of temozolomide
when given together with sorafenib to compare how well they work in treating patients with
metastatic or unresectable melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania University of Pennsylvania